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Background
Effective determinations of sample size require interaction between 
statisticians and their research collaborators who wish to initiate 
studies. The majority of grant applications, clinical trial protocols, 
and IRB submissions will not be approved unless there is some 
statistical justification for the planned sample size that is appropriate 
for the study’s primary objective [1]. However, obtaining a suitable 
sample size is non-trivial and may necessitate dynamic conversations 
regarding aims, objectives, study design, and future directions. Such 
conversations may address the types of data to be collected, analytic 
plans, and whether the specified endpoints and objectives will answer 
the goals of the study post-completion. 
Beyond meeting the challenge of satisfying reviewers, a well-
informed sample size justification will ensure reasonable precision in 
estimation and adequate statistical power for hypothesis tests. Such 
a justification is also made in the context of proposing a budget and 
assessing feasibility of the study design. The sample size must be 
sufficient to test the primary objective and large enough to obtain 
preliminary data for secondary objectives and correlative studies; 
but an excessive sample size may be seen as wasteful and perhaps 
even unethical, if unnecessarily many subjects are randomized to an 
ineffective treatment. This editorial, based in part on the authors’ own 
real-world experiences, is directed to statisticians and will highlight 
some important factors to consider and discuss with collaborators to 
ensure proper study design, endpoint collection, and sample size. Some 
such factors may be easy to overlook, even for a statistician, while some 
pertain to finding common ground with scientists whose statistical 
training may be limited.
Outcomes and Objectives
All research proposals begin with aims. The primary objective 
will influence all aspects of a study, including but not limited to 
data collection, sample size, design, and analytic plans. Therefore, 
the primary objective is an excellent starting point for discussions 
between statisticians and collaborators, as specifying succinct aims and 
appropriate endpoints will drive the rest of the design process.
Aims versus endpoints
Sometimes a collaborator may struggle with identifying aims and 
corresponding endpoints. An outcome measure, also called an endpoint, 
relates to the parameter of interest in a study aim; however, outcomes 
are not synonymous with aims. An outcome is a patient-level measure 
of effect. Ideally, endpoints should be valid and reliable, quantifiable, 
easy to observe, free of measurement error, capable of being observed 
independently of the treatment assignment, and clinically relevant [2]. 
Aims must be clear, concrete, and inclusive of outcomes that can be 
measured in a realistic timeframe. They must be more specific than 
whether the treatment “works”; one question to ask is, “How will 
you determine that treatment is effective and worth future research 
for your patient population?” Writing a hypothesis can also help to 
clarify an aim and guide the analytic plan. During an introductory 
meeting, a statistician may find it helpful to ask collaborators for a five-
minute synopsis of their overall study goals. From that, a statistician 
may readily identify the overarching aims of the study and help the 
collaborator to word them precisely but succinctly. However, further 
information may be required to ascertain what type of data should be 
collected. Asking questions may help to clarify this. Examples include: 
1. “How often and for how long will you follow up with your 
subjects to obtain endpoints?” 
2. “How do you imagine the data looking at the end of the trial?” 
3. “If your aim is to show that a particular treatment is better, what 
information do we need to collect to definitively achieve this aim?”
For oncological and other clinical trials, endpoints differ by each 
phase in drug development. Phase I trials aim to assess safety and 
identify an appropriate dose; consequently, the corresponding endpoint 
must be, or at least encompass, a toxicity outcome [3]. These studies are 
typically single arm, non-randomized trials whose results are analyzed 
mainly with descriptive statistics rather than formal hypothesis tests. 
Phase II studies look for hints of efficacy that would warrant Phase III 
trials. Phase II trials often assess surrogate endpoints, clinical response 
rates, and percentages of patients that “succeed” with the treatment, as 
defined for a particular trial prior to its initiation. They can be single 
arm studies with historical control comparisons, but recently there has 
been a call for randomized Phase II trials [4]. In Phase III trials, the goal 
is to show definitive clinical benefit with a head-to-head comparison 
involving at least two groups, which ordinarily requires time-to-event 
endpoints such as disease progression, mortality, heart attack or stroke, 
and so forth.
Statisticians can help investigators to ensure that their aims match 
the appropriate phase of drug development. In fact, statisticians may 
occasionally help collaborators planning a Phase II study to realize that 
a Phase I trial ought to be conducted first. This may be the case when, 
for example, the referenced dose is unsuitable for the targeted patient 
population or not yet tested in combination with another drug. 
Primary outcomes
Virtually all studies will have multiple questions; however, the 
primary question should be the most clinically important and will 
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drive the study design. Ideally, a single response variable should be 
identified to answer the primary question [5]. If more than one is used, 
the probability of getting a nominally significant result by chance alone 
is increased, unless one incorporates a multiplicity correction; but then 
statistical power is sacrificed. 
Secondary aims and correlatives
Secondary aims are important but do not drive design. In 
phase I trials, these can include descriptions of pharmacokinetics, 
pharmacodynamics, or preliminary clinical responses. In phase II 
studies, secondary objectives can be to estimate overall survival, 
describe safety, evaluate changes in biomarkers, assess quality of 
life measures, or address subsidiary questions relating to a patient 
subgroup. However, all secondary aims should be specified before 
data collection and limited in number. Moreover, principles similar 
to those previously articulated still apply for writing secondary aims 
and determining corresponding outcomes. Relevant questions for a 
statistician to discuss with a collaborator may include:
1. “What is the biologic rationale for these additional aims?” 
2. “Will samples collected come from biopsy tissue or blood, and if 
so is collection of patient samples in a pre-post design feasible?” 
3. “Will the additional effort to acquire these endpoints add to the 
scientific knowledge gained from your study, and is the effort worth the 
time, money, and resources?” 
Additionally, sketching an excel spreadsheet shell may be helpful 
to see what data the investigators plan to collect (regardless of what 
data management program will be used). Since researchers are 
generally familiar with excel, such a sketch can provide a springboard 
for discussing which outcomes are most critical, how often they will 
be measured, how they will be categorized, and so forth. This step can 
help researchers to visualize how their data will look at the end of the 
trial and may identify data collection needs that have been overlooked.
Sample Size Considerations
The basics
After the aims are specified and corresponding endpoints identified, 
sample size calculations may commence; however, there are many 
factors to consider. The three basic components include alpha, beta, 
and delta (clinically relevant difference), as detailed in Table 1. Alpha is 
chosen a priori and typically set to 0.05. In phase II clinical trial or pilot 
studies, some investigators will set alpha=0.10 or 0.15, although this is 
not as common [4]. 
Power is equal to 1-beta and is typically set to 80% (or sometimes 
90% for confirmatory studies). If power is too low, then there is little 
chance of rejecting the null even if the alternative is true, which 
is potentially disastrous given that substantial resources are often 
invested in a study. Assuming that the clinically relevant difference has 
not been mis-specified (see next paragraph), the cause of low power is 
inadequate sample size [6]. Perhaps counter intuitively, one may also 
have power that is too high. For instance, doubling the sample size 
starting from 50% power may lead to 79% power, whereas doubling 
the sample size starting from 98% power may yield 99.99% power. 
Since one was already very unlikely to commit a Type II error at 98% 
power, the doubling of that sample size may be seen as wasteful and 
even unethical.
The minimum clinically relevant difference (CRD or delta) is 
often the most difficult piece of information to obtain pre-study. The 
minimum CRD relates specifically to the primary endpoint. Depending 
on the variable type, this can be a percentage, mean (expressed relative 
to a corresponding standard deviation), median (expressed relative to 
a corresponding range or inter-quartile range), or hazard ratio. The 
minimum CRD can sometimes be informed by pilot data or other 
published studies, but in any case there must be a clinical justification: 
what treatment effect would ultimately change clinical practice [7]? 
Importantly, statistical significance does not imply clinical significance, 
and therefore the minimum CRD may not be what was observed 
previously. Of course, investigators sometimes have little or no pilot 
data to inform specification of the minimum CRD. In such cases, a 
statistician may aid them by sketching suitable diagrams. For instance, 
Figure 1 depicts two partially overlapping bell curves corresponding to 
two different choices of the minimum CRD for a normally distributed 
endpoint. Then investigators may select which, if either, diagram they 
think may represent a realistic expectation for the data they intend to 
collect. 
Types of endpoints
Among several other possibilities, endpoints can be continuous, 
binary, or time-to-event. There are pros and cons to each type, and 
some study designs will naturally favor one type over the others. 
Nonetheless, this choice will influence both the sample size calculation 
and the selection of statistical methodology for the data analysis plan. 
Categorical data are easy to describe and interpret, but caution is 
required because such data usually require greater sample sizes. For 
example, a binary outcome can only be a “0” or a “1”, so variability 
between groups is thereby limited. In fact, there is usually a substantial 
loss of power when inherently continuous data are categorized. 
Additionally, there is potential ambiguity in the selection of cut points 
for such categorizations, which may preclude comparisons across or 
meta-analysis of related studies [8]. 
Number of groups
When there are two or more groups, the investigators need to 
decide upon randomization, blinding, and treatment allocation. 
Regarding the latter, the most practical option is usually 1:1 group 
allocation, as this generally yields optimal or near-optimal power 
for the total sample size. However, there are some situations where 
assigning more subjects to a new procedure may enhance enrollment 
and mitigate ethical concerns about exposing subjects to a riskier or 
potentially less effective treatment.
For continuous outcomes with at least three groups, there are 
sample size formulas for the ANOVA F test. However, the investigator's 
Definition What does this mean 
clinically?
Alpha-α
(Type I Error probability)
Significance Level of 
a test
Probability of rejecting 
the null hypothesis when 
it is true
Superiority Setting-Falsely 
claiming a difference
Non-inferiority Setting-Falsely 
claiming a similarity
Beta-β
(Type II Error probability) 
Complementary to 
power of a test
Probability of failing 
to reject a false null 
hypothesis
Superiority Setting-Falsely 
claiming no difference
Non-inferiority Setting-Falsely 
claiming a difference
Delta-δ (Minimum 
Clinically Relevant 
Difference or CRD)
What is the minimum 
treatment effect that 
would ultimately change 
clinical practice?
Superiority-lower bound 
on efficacy advantage of 
treatment
Non-inferiority-upper bound 
on efficacy disadvantage of 
treatment
Table 1: Basic components for sample size calculations.
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true interest usually lies in the post-hoc comparisons between specific 
groups. A statistician calculating a sample size to power a post-hoc 
comparison must take into account the Bonferroni or other adjustment 
for multiple such comparisons. This is unfortunately easy to overlook, 
and failing to take into account such an adjustment may result in 
grossly underpowered comparisons between specific groups.
Withdrawals and non-compliance
Missing outcome data may arise when subjects are lost to follow 
up, withdraw consent, die, or refuse to answer. There are also situations 
in which subjects (or even study personnel) do not comply with the 
treatment or protocol. If missing outcome data are anticipated, then 
sample size estimates should be adjusted accordingly. For instance, if 
20% of subjects are anticipated to drop out, then sample size estimates 
should be inflated by a minimum of 25%. In such a case, a statistician 
may also wish to incorporate some type of imputation into the data 
analysis plan.
Parametric assumptions
Also important, both to sample size calculations and to 
development of the data analysis plan, are discussions of assumptions 
for parametric tests. This is because nonparametric tests usually 
have less statistical power than parametric tests. Thus, choosing a 
sample size in anticipation of a parametric test and discovering later 
that a nonparametric test is required will lead to an underpowered 
comparison. Reviewing literature from other studies that use similar 
outcomes can be very helpful to assess whether the need for a 
nonparametric test is at least somewhat likely. If so, then inflating the 
sample size by 10-15% a priori may be a good idea. 
Even for parametric tests, there may be some pitfalls to using 
standard sample size formulas. For instance, when employing a T test 
to compare two groups on a continuous outcome, the usual sample size 
formula actually involves quantiles of a Z distribution. They are meant 
to approximate quantiles of a T distribution, but the degrees of freedom 
for that T distribution are unknown since they depend on the sample 
size that one is trying to determine. If investigators hope to justify a 
sample size in the neighborhood of 5 to 15, this Z approximation to a 
T quantile may result in unexpectedly low power. As a practical rule of 
thumb, adding two subjects per group to whatever answer is obtained 
with the Z approximation works surprisingly well. 
Conclusion 
The study aims and corresponding outcome measurements influence 
all other aspects of study design, including sample size calculations 
and formulation of a statistical analysis plan. As shown in Figure 2, 
altering simply one factor within a study design can cause the sample 
size to change significantly. Writing aims well is challenging because 
an investigator must convince readers that the aims are both achievable 
and worthwhile. A further challenge emerges because the process of 
study design is not always linear. For instance, upon completion of a 
sample size calculation, an investigator may change his/her aims to 
avoid prohibitive expenses [2]. Likewise, accrual limitations may have 
implications for study design. Ongoing interactions among the entire 
Figure 1: Example of bell curves to visualize minimum CRD.
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size 
increase↑
Decrease 
Alpha ↓
Conducting a 
2-sided test 
versus 1-
sided
Decrease 
Follow-up 
time and/or 
accrual time 
↓
Decrease 
minimum 
CRD ↓
Increase 
Power ↑
Figure 2: Factors that cause sample size to increase when keeping all other 
considerations constant.
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research team, including the statistician(s), can provide solutions, or at 
least alternatives, when difficulties arise. Beyond that, statisticians must 
also help investigators to avoid common errors, such as those described 
above and one other noted by Kramer and Kupfer [9]: “One common 
mistake in [study design] is guaranteeing adequate power, not at or 
above the threshold of clinical significance, but at or above the desired 
or hoped-for effect size or one based on very optimistic, underpowered, 
pilot studies.” Taking time prior to study initiation to discuss objectives 
and sample sizes is critical, since a poorly designed study cannot be 
fixed and may not even be salvageable post-completion [10].
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